Dyad Labs Revenue and Competitors
Estimated Revenue & Valuation
- Dyad Labs's estimated annual revenue is currently $5.5M per year.
- Dyad Labs's estimated revenue per employee is $189,000
Employee Data
- Dyad Labs has 29 Employees.
- Dyad Labs grew their employee count by -3% last year.
Dyad Labs's People
Name | Title | Email/Phone |
---|
Dyad Labs Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.1M | 33 | 6% | N/A | N/A |
#2 | $8.4M | 39 | -2% | N/A | N/A |
#3 | $61.8M | 208 | 12% | N/A | N/A |
#4 | $12.9M | 53 | 0% | N/A | N/A |
#5 | $9.9M | 46 | N/A | N/A | N/A |
#6 | $7.3M | 34 | 3% | N/A | N/A |
#7 | $208.6M | 618 | 8% | N/A | N/A |
#8 | $17M | 70 | 30% | N/A | N/A |
#9 | $135.7M | 402 | 1% | N/A | N/A |
#10 | $476.1M | 1233 | 10% | $580M | N/A |
What Is Dyad Labs?
Dyad Labs (formerly known as Genysis Labs) is an ISO/IEC 17025:2005 accredited contract laboratory providing specialized chemistry and microbiology testing services to the Nutraceutical and Food & Beverage industries since 2008. Dyad Labs’ mission is to professionally, effectively, and ethically perform testing for our customers to produce accurate and precise results while offering exceptional customer service and support by meeting and exceeding customer expectations. Led by a management team of experts that have diverse backgrounds in pharmaceutical, nutraceutical, and bioanalytical research fields, Dyad Labs is constantly working on new technologies that offer cutting edge solutions to increasing regulatory requirements and calls for full transparency of the supply chain.
keywords:N/AN/A
Total Funding
29
Number of Employees
$5.5M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15M | 29 | -17% | N/A |
#2 | $2.9M | 29 | 16% | N/A |
#3 | $2.4M | 29 | -38% | $7.5M |
#4 | N/A | 29 | -3% | N/A |
#5 | $4.6M | 29 | 12% | N/A |